This is paper was originally published in BioMed Research International, Volume 2016, by Tomas Gabriel Bas and Carolina Oliu Castillo under a Creative Commons Attribution License Abstract The development of…
The post Biosimilars in Developed and Develo…
Although many areas of contention exist in trade relations between the United States and China, ties are strengthening between the two countries, particularly in the areas of science and technology.…
The post China and Potential Opportunity for Pharmac…
China and Potential Opportunity for Pharmaceutical Investments Read Post »
Headlines about high drug prices are nothing new. The high cost of bringing new drugs to market, plus high merger and acquisition activity in pharmaceuticals have led to price increases…
The post Evolving Pharmaceutical Strategies in a Post-Blockbuster…
Evolving Pharmaceutical Strategies in a Post-Blockbuster World Read Post »
India’s pharmaceutical industry has grown tremendously over the past thirty years and is now the world’s third largest drug producer as measured by volume. Hyderabad is one of India’s major…
The post Balancing Opportunity and Risk in India’s Pharmaceut…
Balancing Opportunity and Risk in India’s Pharmaceutical Sector Read Post »
Combination products are a key aspect of personalized medicine, offering more targeted treatment to patients The era of personalized medicine approaches more closely with each passing day, and with it…
The post Patents for Personalized Medicine: Challe…
Patents for Personalized Medicine: Challenges and Opportunities Read Post »
This article was originally published by Ravi Gupta, Thomas J Bollyky, Matthew Cohen, Joseph S Ross, and Aaron S Kesselheim in BMJ 2018;360:k831 under a Creative Commons Attribution Non Commercial (CC BY-NC…
The post Affordability and availability of …
FLO-PRED (prednisolone acetate) Taro Patent: 6,399,079 Expiration: Jun 3, 2018 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or…
The post Drug Pat…
Drug Patent Expirations for the Week of June 3, 2018 Read Post »
Officially known as Approved Drug Products With Therapeutic Equivalence Evaluations, the FDA Orange Book contains a list of drugs considered by the FDA as both effective and safe. It does…
The post 3 Uses for Historical Versions of the FDA Orange Book …
3 Uses for Historical Versions of the FDA Orange Book Read Post »
While the Patent Trial and Appeal Board invalidates Orange Book-listed patents less than 20 percent of the time, it accepts 66 percent of petitions from generic drugmakers and takes no…
The post What We Know From 4-Plus Years of Drug Patent Chall…
What We Know From 4-Plus Years of Drug Patent Challenges Heard by the PTAB Read Post »
SKLICE (ivermectin) Arbor pharms llc Patent: 6,103,248 Expiration: May 22, 2018 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected]…
The pos…
Drug Patent Expirations for the Week of May 20, 2018 Read Post »
Get new actionable insights and updates from BiotechBlog
